Mortality in the TRACER and ATLAS ACS 2 trials: Two more reasons to audit vital records in PLATO

Cardiology (Switzerland)

Volumn 123, Issue 1, 2012, Pages 11-14

  Serebruany, Victor L ^a   Dinicolantonio, James J ^a   Can, Mehmet Mustafa ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Acute coronary syndromes; Clinical trials; Mortality rates; Ticagrelor

Indexed keywords

CLOPIDOGREL; RIVAROXABAN; TICAGRELOR; VORAPAXAR;

ACUTE CORONARY SYNDROME; BRAIN HEMORRHAGE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; DISEASE SEVERITY; FOLLOW UP; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MEDICAL AUDIT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT DURATION;

ACUTE CORONARY SYNDROME; CLINICAL TRIALS AS TOPIC; HUMANS; MEDICAL AUDIT; PLATELET AGGREGATION INHIBITORS; RISK; SURVIVAL RATE; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84865589563     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000342085     Document Type: Review

References (6)

1. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, the PLATO Investigators: Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
2. Serebruany VL: Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified. Thromb Haemost 2011; 105: 752-759.
3. Wallentin L, Becker RC, James SK, Harrington RA: The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Thromb Haemost 2011; 105: 760-762.
4. Ohman EM, Roe MT: Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Thromb Haemost 2011; 105: 763-765.
5. Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Leonardi S, Rorick TL, Kilian AM, Jennings LH, Ambrosio G, Bode C, Cequier A, Cornel JH, Diaz R, Erkan A, Huber K, Hudson MP, Jiang L, Jukema JW, Lewis BS, Lincoff AM, Montalescot G, Nicolau JC, Ogawa H, Pfisterer M, Prieto JC, Ruzyllo W, Sinnaeve PR, Storey RF, Valgimigli M, Whellan DJ, Widimsky P, Strony J, Harrington RA, Mahaffey KW, the TRACER Investigators: Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012; 366: 20-33.
6. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM, the ATLAS ACS 2-TIMI 51 Investigators: Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9-19.